Stockscreener 앱 받기
47.30
0.11%
0.05
시간 외 거래:
47.53
0.23
+0.49%
전일 마감가:
$47.25
열려 있는:
$47.83
하루 거래량:
2.04M
Relative Volume:
1.67
시가총액:
$4.03B
수익:
$170.10M
순이익/손실:
$-239.59M
주가수익비율:
-10.58
EPS:
-4.47
순현금흐름:
$-191.20M
1주 성능:
-13.78%
1개월 성능:
-3.31%
6개월 성능:
-15.87%
1년 성능:
-30.33%
1일 변동 폭
$46.71
$48.28
1주일 범위
$46.30
$53.99
52주 변동 폭
$43.42
$91.10
크리스퍼 테라퓨틱스 Stock (CRSP) Company Profile
명칭
Crispr Therapeutics Ag
전화
(617) 315-4600
주소
BAARERSTRASSE 14, ZUG
CRSP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| CRSP | 47.30 | 4.03B | 170.10M | -239.59M | -191.20M | -4.47 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
크리스퍼 테라퓨틱스 Stock (CRSP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-11 | 다운그레이드 | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | 개시 | Mizuho | Buy |
| 2023-08-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-04-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-03-17 | 개시 | Bryan Garnier | Buy |
| 2023-03-07 | 개시 | Robert W. Baird | Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Underweight |
| 2022-08-09 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-04-21 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-03-04 | 개시 | JMP Securities | Mkt Outperform |
| 2020-12-10 | 재확인 | Chardan Capital Markets | Buy |
| 2020-12-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-10 | 재확인 | Needham | Buy |
| 2020-12-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | 개시 | BofA Securities | Buy |
| 2020-07-28 | 재확인 | Needham | Buy |
| 2020-07-14 | 개시 | SunTrust | Buy |
| 2020-06-15 | 재확인 | Canaccord Genuity | Buy |
| 2020-03-05 | 개시 | Stifel | Hold |
| 2020-02-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-11-19 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-08-01 | 개시 | Jefferies | Buy |
| 2019-07-26 | 개시 | Canaccord Genuity | Buy |
| 2019-06-10 | 개시 | ROTH Capital | Buy |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-14 | 개시 | William Blair | Mkt Perform |
| 2019-01-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-01-22 | 다운그레이드 | Citigroup | Neutral → Sell |
모두보기
크리스퍼 테라퓨틱스 주식(CRSP)의 최신 뉴스
CRISPR Therapeutics AG (CRSP): Among ARK Invest’s Top Stock Picks for 2024 - Insider Monkey
Is It Too Late to Buy Viking Therapeutics Stock? - The Motley Fool
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More - Yahoo Finance
Gene Editing Tools Market Size, Growth Opportunities, - openPR
First Week of July 2025 Options Trading For CRISPR Therapeutics (CRSP) - Nasdaq
CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference - GlobeNewswire
Van ECK Associates Corp Sells 78,228 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Crispr therapeutics CEO Samarth Kulkarni sells shares worth $1.67 million - Investing.com India
Crispr therapeutics CEO Samarth Kulkarni sells shares worth $1.67 million By Investing.com - Investing.com UK
Sumitomo Mitsui Trust Group Inc. Has $139.44 Million Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Baillie Gifford & Co. Lowers Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (CRSP) Stock Analysis: An Unexpected Rise Amidst A Flat Market - Barchart
CRISPR Therapeutics' SWOT analysis: gene editing pioneer faces casgevy launch challenges - Investing.com India
Crispr Therapeutics Q3 EarningsNo Casgevy Revenue, But Plenty Of Optimism (NASDAQ:CRSP) - Seeking Alpha
(CRSP) Investment Analysis - Stock Traders Daily
What is Chardan Capital's Estimate for CRSP FY2024 Earnings? - MarketBeat
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates - MSN
What is Leerink Partnrs' Forecast for CRSP FY2024 Earnings? - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by ARK Investment Management LLC - MarketBeat
CRSP FY2024 EPS Reduced by Brookline Capital Management - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
CRSP's Q3 Loss Narrower Than Expected, Sales Miss Estimates - MSN
CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference - The Manila Times
Here's What Analysts Are Forecasting For CRISPR Therapeutics AG (NASDAQ:CRSP) After Its Third-Quarter Results - Simply Wall St
CRISPR Therapeutics AG (NASDAQ:CRSP) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
CRISPR Therapeutics (NASDAQ:CRSP) Upgraded by StockNews.com to Sell Rating - MarketBeat
Positive Long-Term Outlook for Crispr Driven by Casgevy and Diverse Gene Editing Portfolio - Morningstar
Wall Street Analysts See a 62.75% Upside in CRISPR Therapeutics (CRSP): Can the Stock Really Move This High? - MSN
CRISPR Therapeutics Sell rating reiterated on recent performance - Investing.com
Barclays Has Lowered Expectations for CRISPR Therapeutics (NASDAQ:CRSP) Stock Price - MarketBeat
Leerink cuts CRISPR Therapeutics target to $67, keeps Outperform By Investing.com - Investing.com Canada
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - GlobeNewswire
Leerink cuts CRISPR Therapeutics target to $67, keeps Outperform - Investing.com
CRISPR Therapeutics (CRSP) PT Lowered to $67 at Leerink Partners - StreetInsider.com
Crispr Therapeutics earnings beat by $0.41, revenue fell short of estimates - Investing.com
CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 4%Time to Sell? - MarketBeat
CRISPR Therapeutics AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
CRSPCRISPR Therapeutics AG Latest Stock News & Market Updates - StockTitan
CRISPR Q3: CASGEVY Expands Global Reach, $1.9B Cash Position as Losses Narrow | CRSP Stock News - StockTitan
CRISPR Therapeutics AG (CRSP) Just Overtook the 20-Day Moving Average - Zacks Investment Research
CRISPR Therapeutics AG (CRSP) Recently Broke Out Above the 50-Day Moving Average - Yahoo Finance
International Assets Investment Management LLC Invests $1.83 Million in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by Capital Advisors Inc. OK - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 7.2%Still a Buy? - MarketBeat
Is CRISPR Therapeutics (CRSP) a Promising Gene Editing Stock? - MSN
크리스퍼 테라퓨틱스 (CRSP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):